Skip to main content
. 2021 Dec 17;4(12):e2139593. doi: 10.1001/jamanetworkopen.2021.39593

Table 3. Adjusted Hazard Ratios Between Area Deprivation Index, Medicare-Medicaid Dual Eligibility, and Mortalitya.

Breastb P value Prostatec P value Lung P value CRC P value
Overall mortality
ADI quintile
Q1 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
Q2 1.12 (1.04-1.20) .002 1.11 (1.04-1.19) .002 1.08 (1.03-1.14) .003 1.16 (1.09-1.23) <.001
Q3 1.19 (1.12-1.27) <.001 1.28 (1.19-1.36) <.001 1.10 (1.04-1.16) .001 1.18 (1.12-1.26) <.001
Q4 1.31 (1.23-1.40) <.001 1.36 (1.27-1.45) <.001 1.21 (1.15-1.28) <.001 1.23 (1.16-1.31) <.001
Q5 1.34 (1.26-1.43) <.001 1.51 (1.42-1.62) <.001 1.21 (1.14-1.28) <.001 1.24 (1.17-1.32) <.001
DE
No 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
Yes 1.22 (1.15-1.29) <.001 1.29 (1.21-1.38) <.001 1.14 (1.09-1.20) <.001 1.23 (1.17-1.29) <.001
Cancer-specific mortality
ADI quintile
Q1 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
Q2 1.20 (1.04-1.39) .01 1.00 (0.82-1.22) .98 1.05 (0.98-1.12) .14 1.21 (1.09-1.33) <.001
Q3 1.21 (1.05-1.40) .008 1.22 (1.02-1.47) .03 1.07 (1.00-1.14) .04 1.27 (1.15-1.40) <.001
Q4 1.31 (1.23-1.40) <.001 1.36 (1.27-1.45) <.001 1.21 (1.15-1.28) <.001 1.23 (1.16-1.31) <.001
Q5 1.50 (1.30-1.72) <.001 1.38 (1.15-1.66) <.001 1.16 (1.09-1.24) <.001 1.33 (1.21-1.47) <.001
DE
No 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
Yes 1.23 (1.10-1.37) <.001 1.29 (1.07-1.55) .007 1.14 (1.08-1.21) <.001 1.29 (1.19-1.40) <.001

Abbreviations: ADI, Area Deprivation Index; CRC, colorectal cancer; DE, Medicare-Medicaid dual eligibility; NA, not applicable; Q1, quintile 1; Q2, quintile 2; Q3, quintile 3; Q4, quintile 4; Q5, quintile 5.

a

Adjusted for age, sex, race and ethnicity, marital status, stage, Elixhauser comorbidity index, surgery, radiotherapy, and chemotherapy. Area Deprivation Index and DE were mutually adjusted.

b

For breast cancer, hormone receptor status was additionally adjusted.

c

For prostate cancer, androgen deprivation therapy was additionally adjusted.